Can cosyntropin cause anaphylaxis?

Anaphylaxis from cosyntropin is exceptionally rare, occurring in fewer than 0.1% of patients. However, because it is possible, the test should be administered in a clinical setting with emergency equipment and personnel trained in anaphylaxis management. Patients with severe allergies or prior severe reactions should inform their healthcare provider before testing.

Is cosyntropin safe for pregnant women?

Cosyntropin is generally considered safe for diagnostic use in pregnancy because it is a single-dose, short-acting peptide with no known fetal toxicity. However, clinical judgment is always warranted. Pregnant women should discuss the necessity of the test with their healthcare provider to ensure benefits outweigh any theoretical risks.

How long do cosyntropin side effects last?

Most cosyntropin side effects are transient, resolving within hours of injection. Injection-site reactions typically fade within a few hours. Hypertension and systemic effects (flushing, tachycardia) resolve as the peptide is metabolized, with a half-life of approximately 15–20 minutes.

Who should avoid cosyntropin testing?

Patients with a documented anaphylactic reaction to cosyntropin or its components should avoid re-exposure. Those with severe, uncontrolled hypertension or acute cardiovascular instability should be carefully evaluated before testing. Clinical judgment and pre-test assessment help identify contraindications.

How does cosyntropin compare to other ACTH stimulation agents?

Cosyntropin is the most commonly used synthetic ACTH substitute. It is preferred over natural ACTH because it is synthetic (reducing allergenic risk compared to ACTH derived from porcine pituitary), stable, and consistent. Its safety and efficacy profile have been well-established over decades of clinical use.

Cosyntropin Side Effects & Safety Profile

Cosyntropin is an FDA-approved synthetic peptide that mimics adrenocorticotropic hormone (ACTH) and is used diagnostically to test adrenal gland function. Side effects are generally uncommon and mild, with the most frequently reported being allergic reactions, hypertension, and injection-site reactions. Because cosyntropin is typically administered as a single diagnostic injection rather than ongoing therapy, serious adverse events are rare. Most patients tolerate the medication well, though individual sensitivity varies.

Understanding Cosyntropin's Role

Cosyntropin is a 24-amino-acid peptide that replicates the first 24 amino acids of naturally occurring ACTH. The FDA approved cosyntropin in 1972 as a diagnostic agent for the ACTH stimulation test, which evaluates whether the adrenal glands respond appropriately to hormonal signaling. This test helps clinicians diagnose conditions like Addison's disease, secondary adrenal insufficiency, and certain pituitary disorders.

Because cosyntropin is administered in a single, short diagnostic protocol—not as chronic medication—its safety profile differs from long-term peptide therapies. Clinical evidence from over 38 documented trials demonstrates that adverse events are infrequent and usually self-limited.

Most Common Side Effects

Allergic Reactions

The most frequently observed adverse effect is hypersensitivity or allergic reaction. Studies indicate that allergic responses occur in approximately 1–3% of patients, manifesting as:

Rash or urticaria (hives)
Pruritus (itching)
Flushing
Rarely, anaphylaxis

These reactions are thought to stem from the peptide's foreign nature—even though cosyntropin is synthetic, the immune system may recognize it as non-self. Patients with a history of allergies or atopy face slightly elevated risk. Pre-test screening for allergy history is standard practice and helps identify those who may benefit from premedication or close monitoring.

Hypertension

Temporary elevation in blood pressure is another notable side effect, reported in clinical experience. Cosyntropin stimulates cortisol release from the adrenal cortex, and cortisol is a potent vasoconstrictor and sodium-retaining hormone. Research on ACTH-stimulated cortisol release shows that acute increases in cortisol can transiently raise blood pressure, though the effect is typically modest and resolves within hours of the injection.

Patients with baseline hypertension or those on antihypertensive medications should have their blood pressure monitored before and after the test. The elevation is rarely clinically significant in otherwise healthy individuals but warrants awareness in those with cardiovascular risk factors.

Injection-Site Reactions

Local reactions at the injection site are uncommon but can include:

Mild pain or discomfort
Erythema (redness)
Edema (swelling)

These typically resolve spontaneously within hours and do not usually require intervention.

Less Common Adverse Events

Comprehensive safety reviews of cosyntropin clinical trials document rare adverse effects including:

Tachycardia: Rapid heart rate in response to acute cortisol elevation.
Dizziness or vertigo: Likely related to rapid physiological changes.
Nausea: Reported in fewer than 1% of patients.
Headache: Uncommon and usually mild.
Tremor: Rare, possibly related to sympathetic activation from cortisol surge.

Serious adverse events—such as myocardial infarction, stroke, or severe anaphylaxis—are exceptionally rare given the single-dose, diagnostic nature of the test. When serious events have been documented, they typically occur in patients with significant underlying comorbidities.

Risk Factors & Contraindications

Certain populations face elevated risk:

Allergic Diathesis: Patients with prior anaphylaxis, severe allergies, or known hypersensitivity to cosyntropin should not receive the test, or should do so only with appropriate medical supervision and access to emergency intervention.

Cardiovascular Disease: Those with a history of myocardial infarction, unstable angina, or uncontrolled hypertension may experience exaggerated pressor responses. Clinical guidelines recommend cardiovascular assessment before cosyntropin stimulation testing in high-risk patients.

Adrenocortical Carcinoma: Cosyntropin stimulation may theoretically exacerbate hormone secretion in patients with adrenocortical tumors, though this is rare given that such patients are typically identified before testing.

Pregnancy: Although data are limited, cosyntropin is generally considered safe in pregnancy for diagnostic purposes. The acute hormonal change does not pose recognized fetal risk, but individual clinical judgment is warranted.

How Cosyntropin Differs from Other Peptides

Cosyntropin's safety profile is favorable compared to longer-acting peptide therapies. Unlike sustained-release compounds such as somatostatin analogs or growth hormone-releasing peptides, which are often used chronically, cosyntropin is a single-injection diagnostic tool. This means cumulative toxicity, long-term metabolic effects, and chronic immune activation are not concerns. The peptide is rapidly cleared from circulation, with a half-life of approximately 15–20 minutes, minimizing prolonged exposure.

For comparison, investigational peptides and compounds like ARA-290 are being studied for chronic conditions and carry different safety considerations tied to repeated dosing and long-term biological effects.

Managing & Minimizing Risk

Standard clinical practice minimizes cosyntropin-associated adverse effects:

Pre-Test Screening: Healthcare providers obtain detailed allergy and medical histories, identify contraindications, and assess cardiovascular risk.
Medical Supervision: The test is administered in a clinical setting where staff can monitor vital signs and respond to adverse events.
Emergency Preparedness: Facilities performing cosyntropin testing maintain access to emergency medications, including epinephrine for anaphylaxis.
Timing Considerations: Testing is often scheduled in the morning to align with natural circadian ACTH rhythms and may allow for same-day assessment.
Patient Education: Clear pre- and post-test instructions help patients understand what to expect and recognize any concerning symptoms.

The Evidence Base

Decades of clinical use—with over 38 registered clinical trials documenting cosyntropin's diagnostic utility and safety (registered on ClinicalTrials.gov)—support the conclusion that serious adverse effects are rare. Regulatory approval by the FDA reflects a favorable benefit-risk profile: the diagnostic information gained significantly outweighs the low probability of meaningful harm in appropriately screened patients.

Physicians continue to use cosyntropin as a first-line diagnostic agent for adrenal insufficiency because it is both effective and generally well-tolerated.

Key Takeaways

Cosyntropin side effects are infrequent and usually mild, with allergic reactions and transient hypertension being the most notable. The peptide's short half-life and single-dose diagnostic protocol mean that cumulative toxicity is not a concern. Proper patient screening, medical supervision, and emergency preparedness effectively mitigate risk. For the vast majority of patients undergoing cosyntropin stimulation testing, the procedure is safe and well-tolerated.

What Are the Side Effects of Cosyntropin?